The Clinical Trials Unit Resource (CTUR) component ofthe CDU/UCI^ Cancer Center Partnership will be charged with the overarching goal of enhancing minority participation in clinical research and clinical trials. The accomplishment of this goal will further develop the institutional capacity at CDU in the area of cancer-related clinical trials by leveraging existing clinical research facilities and resources. Specifically, the partnership will enhance the established Clinical Research Center (CRC) at CDU;the clinical trials component ofthe CRC, called the Clinical Center for Research Excellence (CCRE), was developed to enhance CDU's infrastructure for clinical studies and is headed by Dr. Mayer Davidson. The CDU-UCLA partnership will continue to build upon the current infrastructure to enhance the ability to conduct effective clinical studies in cancer heath disparities. The specific objectives of the Resources activities are as follows:
Specific Aim 1 : Enhance the recruitment and retention of racial and ethnic minorities into clinical trials related to cancer at the CRC;
Specific Aim 2 : Provide training and assistance in the design, development, and execution of CDU clinical cancer research studies;
Specific Aim 3 : Communicate and solicit feedback regarding clinical trials with the community via the Outreach Program;
and Specific Aim 4 : Employ external reviewers to assess the quality and strength ofthe clinical results. These reviewers will be engaged at the eariiest onset to provide input in the development of clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA143930-05
Application #
8543593
Study Section
Special Emphasis Panel (ZCA1-SRLB-D)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$92,470
Indirect Cost
$31,648
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Wu, Yanyuan; Sarkissyan, Marianna; Vadgama, Jaydutt V (2016) Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med 5:
Maxwell, Annette E; Danao, Leda L; Cayetano, Reggie T et al. (2016) Implementation of an evidence-based intervention to promote colorectal cancer screening in community organizations: a cluster randomized trial. Transl Behav Med 6:295-305
Wang, Piwen; Henning, Susanne M; Magyar, Clara E et al. (2016) Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin Cancer Res 35:73
Ceribelli, Michele; Hou, Zhiying Esther; Kelly, Priscilla N et al. (2016) A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Cell 30:764-778
Maxwell, Annette E; Young, Sandra; Rabelo Vega, Roena et al. (2015) Building Capacity to Address Women's Health Issues in the Mixtec and Zapotec Community. Womens Health Issues 25:403-9
Wu, Yanyuan; Sarkissyan, Marianna; Vadgama, Jaydutt V (2015) Epigenetics in breast and prostate cancer. Methods Mol Biol 1238:425-66
Hamilton, Nalo; Márquez-Garbán, Diana; Mah, Vei et al. (2015) Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int 2015:925703
Mott, Bryan T; Eastman, Richard T; Guha, Rajarshi et al. (2015) High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Sci Rep 5:13891
Ortiz-Meoz, Rodrigo F; Jiang, Jiaoyang; Lazarus, Michael B et al. (2015) A small molecule that inhibits OGT activity in cells. ACS Chem Biol 10:1392-7
Wu, Yong; Sarkissyan, Marianna; Mcghee, Eva et al. (2015) Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. Breast Cancer Res Treat 151:529-39

Showing the most recent 10 out of 36 publications